Heather Raymon - 12 Dec 2025 Form 4 Insider Report for Artiva Biotherapeutics, Inc. (ARTV)

Role
SVP, Research and Development
Signature
/s/ Andrew Cronauer, Attorney-in-Fact
Issuer symbol
ARTV
Transactions as of
12 Dec 2025
Net transactions value
$0
Form type
4
Filing time
12 Dec 2025, 19:21:14 UTC
Previous filing
17 Nov 2025
Next filing
18 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Raymon Heather SVP, Research and Development C/O ARTIVA BIOTHERAPEUTICS, INC., 5505 MOREHOUSE DRIVE, SUITE 100, SAN DIEGO /s/ Andrew Cronauer, Attorney-in-Fact 12 Dec 2025 0002028466

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARTV Common Stock Award $0 +67,253 +170% $0.000000 106,844 12 Dec 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ARTV Employee Stock Option (Right to Buy) Disposed to Issuer -18,239 -100% 0 12 Dec 2025 Common Stock 18,239 $5.14 Direct F2, F3
transaction ARTV Employee Stock Option (Right to Buy) Disposed to Issuer -12,539 -100% 0 12 Dec 2025 Common Stock 12,539 $5.01 Direct F2, F4
transaction ARTV Employee Stock Option (Right to Buy) Disposed to Issuer -14,819 -100% 0 12 Dec 2025 Common Stock 14,819 $5.01 Direct F2, F5
transaction ARTV Employee Stock Option (Right to Buy) Disposed to Issuer -11,399 -100% 0 12 Dec 2025 Common Stock 11,399 $5.18 Direct F2, F6
transaction ARTV Employee Stock Option (Right to Buy) Disposed to Issuer -10,259 -100% 0 12 Dec 2025 Common Stock 10,259 $13.47 Direct F2, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units award granted under the Issuer's 2024 Equity Incentive Plan ("RSUs").
F2 On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I.
F3 25% of the shares vested on October 22, 2021, and the remaining shares vest in 36 equal monthly installments thereafter.
F4 25% of the shares vested on January 1, 2024, and the remaining shares vest in 36 equal monthly installments thereafter.
F5 25% of the shares vested on February 22, 2022, and the remaining shares vest in 36 equal monthly installments thereafter.
F6 Vesting is monthly over a 48-month period starting January 1, 2024 in equal monthly amounts.
F7 25% of the shares will vest on July 19, 2025, and the remaining shares vest in 36 equal monthly installments thereafter.